NeoStem Inc  

(Public, NASDAQ:NBS)   Watch this stock  
Find more results for NBS
-0.17 (-5.78%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.67 - 2.98
52 week 2.67 - 7.39
Open 2.96
Vol / Avg. 845,086.00/359,190.00
Mkt cap 106.53M
P/E     -
Div/yield     -
EPS -1.65
Shares 38.46M
Beta 1.35
Inst. own 17%
Mar 20, 2015
NeoStem Inc at Biocentury Future Leaders in the Biotech Industry
Feb 9, 2015
NeoStem Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 12, 2015
NeoStem Inc at EBD Biotech Showcase
Jan 12, 2015
NeoStem Inc at OneMedForum SF
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -221.55% -309.20%
Operating margin -294.76% -321.88%
EBITD margin - -312.35%
Return on average assets -36.40% -51.34%
Return on average equity -76.65% -90.66%
Employees 182 -
CDP Score - -


420 Lexington Ave Rm 350
NEW YORK, NY 10170-0303
United States - Map
+1-212-5844171 (Phone)
+1-646-5147787 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NeoStem, Inc. (NeoStem) is a provider of cellular therapy products. The Company is engaged in the development of cell therapy products; it also provides development and manufacturing services. NeoStem�s research and clinical development activities are aimed at three therapeutic platforms: ischemic repair (CD34 Cell Program), immune modulation (T Regulatory Cell Program) and tissue regeneration (VSELTM Technology). The Company develops therapies to address ischemia through its CD34 Cell Program. The Company focuses on the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs, restoring their normal function. The Company�s AMR-001 is the product candidate in its CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) (AMI).

Officers and directors

Robin L. Smith M.D. Executive Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
Robert S. Vaters President, Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
David J. Mazzo Ph.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Robert A. Preti Ph.D. President and Chief Scientific Officer - PCT
Age: 57
Bio & Compensation  - Reuters
Stephen W. Potter Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Joseph Talamo Vice President, Chief Accounting Officer, Corporate Controller
Age: 45
Bio & Compensation  - Reuters
Catherine M. Vaczy Esq Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
David Schloss Vice President, Director of Human Resources
Age: 55
Bio & Compensation  - Reuters
David Altarac Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Andrew L. Pecora M.D. Chief Visionary Officer, Director
Age: 57
Bio & Compensation  - Reuters